Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Wednesday, October 14, 2026

Back to today

October 2026 Random Ramblings

October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI premiums for Oura and home builders.

SBUX $103BCMG $38B
Yet Another Value Podcast 81 clicks

From X

@BrokenMoats 3 clicks

Broken Moats on X

Hottest trade in the past month.....retail stocks Seems odd with rates and oil and diesel moves over the same time frame. And these are not bounces from being oversold these are double digit moves in most cases to new highs while dpz struggled on their print this week, stocks like DKS collapsed around the time this trade started. Bifurcation in retail in recent weeks that seems to be favoring low quality. Something to watch for a reversal soon $KSS $FIGS $URBN $SHOP
@BrokenMoats 3 clicks

Broken Moats on X

Quickly back to very attractive levels to put back on short exposure on the software sector after the manic move in Q3 and digestion in September before the sudden crash up in the past 10 days..... AI wins software is in trouble - faster disruption more competition, pricing pressure AI trade is over, software is going to catch down as the market will tank and this won't sit that out (the are not cheap) Disruption and pricing is the tailwind, now valuation is too. Rates don't hurt either as up until recently these were considered long duration assets Recent results were status quo for most (no real acceleration) and pitch AI cohort growth as growing xx% but its not uplifting the total growth they are just changing what they charge for to show the street what it wants to hear) -- that phase is over, valuations are in many cases at year and multi year highs. SBC still a problem. Now comes renewals in the back of this year and thats where the issues will start to emerge on retention and pricing. An thats day 1 they will snowball overtime for the vast majority of these companies. Plenty of names to choose from: $PAYC $DOCU $TEAM $DDOG $PCTY $GDDY $RNG
@ParadisLabs 3 clicks

Paradis on X

An example that there are always trades in the market. $NAVN +12% in a ~couple weeks while sentiment & flows for semis/bottlenecks has fallen off. If anyone wants a Navan investment thesis: Navan is a corporate travel and expense platform. I believed that the market punished the stock (-22%) after Q2 earnings for no good reason. Plus, I also heard some pretty big investors bought the dip aggressively. It makes sense to follow the flows sometimes when fundamentals align. - Total GBV rose 45% to >$3B driven by new customers, ramping cohorts, and expansion of installed base. - Enterprise customers: Continued momentum in the enterprise market. - AI platform adoption: Over 50% of AI calls now run on Navan's proprietary models, with its AI support agent handling about 60% of customer interactions. Ultimately, investors were disappointed because they reported rising op. costs and expanded op. losses. But the market completely overlooked the fact that corporate traven demand has skyrocketed w/ business travel in the US generating $624B in GDP (Global Business Travel Association). Going forwards, I believe that enterprises will look for AI-native solutions that save them time and money while also resulting in better outcomes for the customer. From what I hear, Navan's AI is pretty sweet. ***I have taken profits to bolster my cash piles. Also, $IOT is flat over the same period.
@stockgutter 2 clicks

SG on X

I asked @grok to assess how the full results that $MRNA plans to release at ESMO that would strengthen or weaken the impression from top line results announced in August. The results are copied below. Seems reasonable to me at first glance (without having checked any of the data cited) -- anyone have a different view? ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Items that could weaken (or further strengthen) the positive view include: - Magnitude of benefit: Hazard ratios (HRs), confidence intervals, absolute risk reductions, and landmark rates (e.g., 1- or 2-year RFS/DMFS). The earlier Phase 2b KEYNOTE-942 showed an RFS HR of ~0.51 (~49% relative risk reduction) and a DMFS HR of ~0.41 at 5 years. A substantially weaker Phase 3 effect (for example, HR closer to 0.75–0.85 with modest absolute benefit) could make the result look less compelling given the complexity, cost, and personalized manufacturing of the therapy. A comparable or stronger effect would reinforce the topline. - Statistical robustness and maturity: Width of confidence intervals, exact p-values, number of events, and median follow-up duration. Narrow intervals and a solid number of events support reliability; wide intervals, low event counts, or very short follow-up at the interim analysis could raise questions about reproducibility or durability. Subgroup consistency: Results by stage (IIB/IIC vs. III vs. IV), age, BRAF status, PD-L1 expression, geography, or other factors. Benefit concentrated in higher-risk stages or selected subgroups would narrow the practical population and commercial opportunity relative to a broadly consistent effect. Durability (Kaplan–Meier curves): Early separation that later plateaus or converges would suggest limited long-term impact. Sustained separation would support durability. - Overall survival signal: Any immature OS HR, death counts, or curve separation. An adverse or flat trend (while not decisive this early) could temper enthusiasm pending mature data. - Safety, tolerability, and feasibility details: Grade ≥3 adverse events, serious AEs, immune-related AEs, discontinuations, quality-of-life/patient-reported outcomes, and any manufacturing metrics (production success rate, turnaround time, or treatment delays). Higher toxicity, discontinuations, or practical barriers could offset efficacy gains. The topline noted consistency with prior experience and no new signals, but granular rates matter. - Stronger, consistent, durable efficacy with manageable safety and feasible delivery would solidify the positive assessment, support regulatory filings, and underpin commercial expectations. Marginal magnitude, inconsistency across key subgroups, limited durability, or meaningful safety/feasibility issues would lead to a more cautious view of clinical utility and value, even though the trial formally met its endpoints.

Investor Letters

All letters

My 2028 numbers

ASML’s €11.7 billion quarter benefited from €3.3 billion in installed-base sales and operating leverage, while the MATCH Act threatens…

ASML $660B
Best Anchor Stocks 22 clicks

Lennar, Part One: The Story

Lennar grew from a Miami builder into one of America’s two largest homebuilders, controlling land largely through options and land banks…

LEN $17B
Latticework by MOI Global 10 clicks

Lennar, Part Two: The Deep Dive

Lennar’s second audio program examines the homebuilder’s business for professional investors and housing analysts.

LEN $17B
Latticework by MOI Global 11 clicks

ASML Q3 FY12/26 Earnings Review

ASML reported Q3 sales of €11.7 billion, up 55% year over year, and guided Q4 sales to €14.2 billion to €15.2 billion amid capacity…

ASML $660B
Cestrian Capital Research 7 clicks
IBIT · long

Ishares Bitcoin Trust Etf

IShares Bitcoin Trust ETF (IBIT) is presented as a high-conviction Bitcoin position with attractive risk-reward.

IBIT $173B
Value Investors Club 2 clicks

Canterra Minerals: Research Note

Canterra Minerals increased Lundberg indicated tonnage 55% to 26.1Mt, with 226.2Kt of contained copper equivalent, supporting a Buchans…

EQX $13B
Atrium Research - Equity Research 1 click

Kenorland Minerals: Research Flash

Franco-Nevada bought 10.0 million Kenorland shares, a 12.4% stake, for C$22.2 million in a secondary transaction that issued no new shares.

FNV $47B
Atrium Research - Equity Research 2 clicks

Is EDA Dead?

Synopsys and OpenAI will share revenue from GPT-Synopsys, an AI chip-design model built on Synopsys’ licensed EDA tools rather than…

SNPS $96B
Chipstrat

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 49 of 227

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.